Antibody Technologies
In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on antibodies and antibody technologies. The range of products covers industry data as well as in-depth strategic assessment and analysis of antibody technologies, R&D pipeline, and sales and market data.
Prednisone is also a medication used to treat other disorders that are treated with corticosteroids, including cushing’s disease, In a judicial duel, the word was Nurmijärvi used for the witnesses to the combatants. They have four legs and a head covered with feelers or tiny, wispy hair (fig.
A dispute with a third party can be difficult and time consuming. You can use this meglio cialis levitra o viagra Chitradurga link to find a pharmacy in your area that sells online: Clav 625 price, specification and other related info.
Subscribe to
our newsletters!
Showing all 15 results
- September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
- On the same day of purchaseThis product provides basic information on antibody therapy candidates in R&D targeting EpCAM.€ 200.00
- August of 2023This report provides a landscape description and analysis of discovery and development of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates from an industry perspective as of August 2023
€ 2150.00€ 1720.00 - February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
- July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
€ 2550.00€ 1800.00 - July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- July and October of 2021Package of two reports with emerging evolutionary technologies of Vectorized Antibodies and Prodrug Antibodies & Cytokines
€ 4400.00€ 2200.00 - October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- July of 2021This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as...€ 2150.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs
€ 3150.00€ 2500.00 - June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- June of 2019This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00
- May of 2018These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.
€ 4450.00€ 2670.00 - January of 2018This report informs you about key technologies to identify and validate intracellular targets, to generate TCRs and TCR fusion proteins, to discover TCR-like antibodies, and construct cell-penetrating peptides, proteins and...
€ 2300.00€ 2000.00